Quantcast

Latest Pneumococcal conjugate vaccine Stories

2011-04-06 11:22:18

Using a cross-sectional study, Stefan Flasche and colleagues investigated the effects of the UK pneumococcal vaccination program on serotype-specific carriage and invasive pneumococcal disease. There are more than 90 Streptococcus pneumoniae serotypes that can cause invasive pneumococcal disease (IPD). The pneumococcal conjugate vaccine PCV7 contains antigens from seven serotypes responsible for IPD. Immunization with PCV7 prevents both IPD disease and carriage of these seven serotypes, but...

2011-03-31 06:30:00

BEIJING, March 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010. Business Highlights In March 2011, Sinovac reported positive preliminary Phase I clinical trial results in adults for its proprietary EV71 inactivated vaccine against hand, foot and mouth disease. Sinovac received approval from China's SFDA (State...

0480a06753f3acdcb32bc3b884fa955d1
2011-03-08 07:35:59

Two widely-used vaccines made by Pfizer and Sanofi-Aventis have been suspended for use in Japan, as the health ministry investigates whether they are linked to the recent deaths of four infants. The vaccines, which are used to prevent meningitis and pneumonia, are Prevenar by New York-based Pfizer and ActHIB by Sanofi Pasteur, a subsidiary of Paris-based Sanofi-Aventis. The infants died shortly after receiving the vaccines. While it is not yet clear if there is a link between the deaths and...

2011-03-03 07:00:00

BEIJING, March 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011. Sinovac initiated its PCV research program in 2008. The vaccine targets infants under two years old. The target population in China is estimated at 34...

2011-02-22 13:09:48

Triggers protective immune response while preventing fatal inflammation Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases. Pneumococcal pneumonia can occur when the lungs are...

2011-02-16 16:43:44

Vaccine inhibits bacteria by mimicking naturally-acquired immunity; collaborators plan to further advance development of the vaccine candidate Pneumococcus (Streptococcus pneumoniae) accounts for as much as 11 percent of mortality in young children worldwide. While successful vaccines like Prevnar® exist, they are expensive and only work against specific pneumococcal strains, with the risk of becoming less effective as new strains emerge. Through a novel discovery approach,...

7cb34e75f48d95930d18ab6893facffd
2011-02-01 13:55:00

Experts say that children will be better protected against pneumonia and other infections caused by the pneumococcus bacterium with this year's updated immunization schedule. The number of vaccinations kids should get has not changed, but authorities now recommend using Pfizer's Prevnar 13 (PCV13), which guards against six more types of pneumococcal bacteria than the earlier version. "Parents should feel very good about immunizing their children," Dr. Neal Halsey, who heads the Institute...

2011-01-31 07:00:00

BEIJING, Jan. 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the submission of the applications to commence human clinical trials for its 23-valent and 24-valent pneumococcal polysaccharides vaccines to the Chinese State Food Drug Administration (SFDA) on January 31, 2011. The preclinical studies were completed and showed good safety and efficacy profile in animal models. Sinovac independently...

2010-12-22 13:43:00

NEW YORK, Dec. 22, 2010 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine. (Logo:...

2010-12-12 04:00:00

NEW YORK, Dec. 12, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. The AMC is an innovative program which involves private-public partnerships to help make newer vaccines available...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related